Nextleaf Solutions Ltd. (“Nextleaf”, “OILS” or the “Company”) (CSE:OILS, OTC:OILFF, Frankfurt:L0MA) today announced that it has added Mr. Tim Gillis to its Board of Directors, effective immediately.

Mr. Gillis most recently led STI Technologies Limited (“STI”), a leading healthcare technology company which connects physicians, patients, pharmacy and pharma with a variety of intelligent reimbursement solutions that empower choice amongst healthcare professionals and patients, ultimately improving patient outcomes. As Chief Executive Officer, Mr. Gillis navigated STI through a period of hypergrowth which culminated in a sale to IQVIA (NYSE: IQV). Mr. Gillis has previously held senior positions with Stantec Inc. (TSX: STN) and Clarke Inc. (TSX: CKI) and throughout his career has completed over $345MM in strategic transactions.


“Tim Gillis is a dynamic leader and is experienced in growing a disruptive technology company in the pharma industry. He is an excellent fit as Nextleaf continues to develop and monetize its intellectual property portfolio focused on industrial-scale cannabis extraction, purification, and derivative formulations” said Paul Pedersen, Chief Executive Officer at Nextleaf. “Tim’s decades of operational and strategic experience in health care technology and the pharma industry will be an asset as we focus on building long term shareholder value.”

“Nextleaf is at an exciting stage with THC and CBD based edibles and concentrates set to become legal across Canadathis October. With its portfolio of issued and pending patents, the Company is well-positioned to capitalize on the global legalization movement,” said Tim Gillis. “I look forward to working with Nextleaf’s management team to leverage my experience in growing a technology company that specialized within the pharmaceutical industry. We are committed to fostering strong corporate governance by implementing best practices and positioning the Company as a technology leader in the cannabis industry.”

Concurrently with the addition of Mr. Gillis to the Board of Directors, Dr. Paul MacLeman has resigned as a director of Nextleaf to focus on his growing Australian business opportunities and commitments. Paul Pedersen said, “we would like to thank Mr. MacLeman for all his support and effort throughout an important stage of Nextleaf’s development.”

Options Grant

The Company has awarded a Director of the Company 150,000 options, pursuant to the Company’s Stock Option Plan, exercisable at a price of $0.50 per common share.

Licensing Update

OILS is pleased to announce the Affirmation of Readiness and Video Evidence Package (the “Evidence Package”) has been submitted to Health Canada for Nextleaf’s built-out extraction and processing facility in Greater Vancouver, British Columbia. The Evidence Package submission is the final step required in order to demonstrate and confirm to Health Canada that a facility is fully built, operationally ready and in compliance with the Cannabis Act, prior to being issued a Standard Processing License. Health Canada has indicated a service standard within 60 days from submission of a completed Evidence Package.

About Nextleaf

Nextleaf Solutions Ltd. (CSE: OILS) is an extraction technology company that has developed a portfolio of issued and pending patents pertaining to the Company’s unique, industrial-scale process of producing purified cannabinoid distillate, a tasteless, odourless cannabis concentrate best suited for infusing premium value-added products. Upon cannabis concentrates becoming legal across Canada on October 17, 2019, Nextleaf plans to commercialize its intellectual property portfolio through B2B processing services to licensed cultivators and the supply of cannabis oils and concentrates to qualified Canadian and international partners.

For more information visit www.nextleafsolutions.com, phone 604-283-2301 (ext. 201), email investors@nextleafsolutions.com, or follow OILS across social media platforms.

CAUTIONARY STATEMENT:
The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of OILS securities in the United States. This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of OILS, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of OILS and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of OILS future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from OILS’ expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to OILS, reference should be made to OILS continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, OILS CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. OILS does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release.

Click here to connect with Nextleaf Solutions Ltd. (CSE:OILS) for an Investor Presentation.

Source: www.newswire.ca

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less